CNTA - Centessa Pharmaceuticals PLC ADR

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to improve patients' lives.

The company's pipeline is built around several promising products, including SerpinPC, an activated protein C inhibitor designed to treat hemophilia A and B, two genetic disorders that affect the blood's ability to clot. Another key product is ORX750, an orally administered OX2R agonist that targets the treatment of narcolepsy, a chronic sleep disorder, as well as other sleep-related conditions.

Centessa is also working on LB101, a bi-specific monoclonal antibody that aims to treat solid tumors by selectively driving potent CD47 and CD3 effector function activity while minimizing systemic toxicity. This approach has the potential to revolutionize cancer treatment by targeting specific cancer cells while sparing healthy cells.

In addition to these products, the company is developing other OX2R Agonists compounds to treat narcolepsy, as well as earlier-stage preclinical assets and discovery-stage programs. This diversified pipeline positions Centessa to make a significant impact in the pharmaceutical industry.

Founded in 2020, Centessa Pharmaceuticals plc is headquartered in Altrincham, the United Kingdom, and is committed to advancing its pipeline through rigorous research and development. For more information, visit their website at https://www.centessa.com.